Clinical Trial Update: A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the safety and tolerability of abrupt discontinuation of saredutant in patients with depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder

Drugs mentioned

• Saredutant (saredutant)

Snippet

Sponsor: Sanofi | Conditions: Depressive Disorder | Phase 3 | Status: COMPLETED